Investors: If you like Compass Pathways you will love M2Bio Sciences.

Shares :


For several weeks now, no one can dispute that the psychedelics market is one of the hottest. Several IPOs since spring (MMED, NUMI, TRIP …) have taken the market to new heights.

But the arrival of Compass Patways on September 17th set the bar very high.

“Compass has reached a value of more than $1.7 billion”

Compass Patways, which is in a phase IIb clinical trial in treatment-resistant depression, has reached a value of more than $1.7 billion today to become the market leader in terms of market value.

$100 billion market according to Cannacord

But are there any companies that are still undervalued in this over $100 billion market according to Cannacord’s latest report ?

M2Bio Sciences, Inc | WUHN on OTC

M2Bio Sciences is increasingly starting to open the eyes of investors with a value of only $22 Million and a float of less than 10 Million.

M2Bio Sciences has a value of only $22 Million and a float of less than 10 Million

The stock closed at its year high of $0.47 and is now in full swing to its last 3 year high of $0.75

WUHN 1 month chart

In addition, the company is self-funded and investors will not find cheap papers.

M2Bio Sciences is one of the only companies in the world to have already carried out an in vitro / in vivo study with psilocybin in animals in 2019 and is preparing for phase 1 human trial as soon as Q1 2021 for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s.

From M2Bio corporate presentation

M2Bio Sciences just announced that they are moving forward with the acquisition of Tsime Pharmaceuticals and the plans to cultivate up to 3 hectares of medicinal-grade cannabis on the farm with a land area covering 23 hectares (57 acres).

According to the company, the project’s first crop is scheduled for Q2-Q3 2021, with projected annual revenue of USD 9.8 Million.

In addition, following a recent series of agreements and acquisitions, M2Bio Sciences Inc | WUHN is preparing to put on the market a series of products based on CBD and Mushroom.

M2Bio Sciences represents a deal compared to its peers and should continue to attract more and more investors in the weeks to come.

For further information:

Publicly traded company (OTC Pink: WUHN)
Follow us on Twitter:
Follow us on Facebook:

Sign up for MORE news updates !

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Disclosure : Wuhan General group inc (M2Bio Sciences Inc) is clients of The Cannabis Stock.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 4

No votes so far! Be the first to rate this post.

Shares :